Abstract
Gene therapy (GT) can correct genetic deficiencies through the modulation of gene expression by gene replacement, addition, silencing, or editing. GT can be administered directly to the patient (in vivo), or in patient-derived cells > (ex vivo), which are then autologously transplanted to the patient. GT delivers nucleic acids [i.e., antisense oligonucleotides (ASOs) or siRNA to silence mRNA], or viral vectors [i.e., lentiviral vectors (LV) for local transduction or adeno-associated viral vectors (AAV) for stable, widespread, and safe gene expression]. Color code: gray represents diseased state, pink indicates therapeutic entities and their effects.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
